Homocysteinemia Is Not Changed by 3-Day Insulin-Induced Normoglycemia in Type 2 Diabetic Subjects
- Marie-Christine Beauvieux, PD, PHD12,
- Vincent Rigalleau, MD, PHD2,
- Caroline Perlemoine, MD2,
- Laurence Baillet, MD2 and
- Henri Gin, MD, PHD2
- 1Laboratoire de Biochimie, Hôpital Haut-Lévêque, Pessac, France
- 2Service de Nutrition et Diabétologie, Hôpital Haut-Lévêque, Pessac, France
- Address correspondence to Marie-Christine Beauvieux, Laboratoire de Biochimie, Hôpital Haut-Lévêque, Avenue de Magellan, 33604 Pessac, France. E-mail: marie-christine.beauvieux{at}chu-bordeaux.fr
Diabetic patients have a two- to sixfold increase in the prevalence of cardiovascular diseases (CVDs) (1). Homocysteinemia is an independent risk factor for CVD (2). Genetic, age- and sex-related, nutritional, and hormonal factors leading to the abnormal regulation of homocysteinemia in diabetes play a role in CVD (3). The relation between homocysteinemia and cardiovascular morbidity remains unclear (4). Type 2 diabetes is the result of insulin resistance paired with a progressive loss of insulin secretion, and the resulting chronic hyperglycemia is associated with long-term CVD. In type 2 diabetes, a 3-day insulin-induced strict normoglycemia improves 1) postprandial carbohydrate oxidation evaluated by indirect calorimetry (5) and 2) parameters of erythrocytic lipoperoxidation, such as malondialdehyde and vitamin E (6). Few studies …
